APX3330 ZETA-1 Clinical Data Presented at American Diabetes Association’s Annual Conference

Ocuphire Pharma, Inc. presented clinical data on their drug APX3330 in a late-breaker session at the American Diabetes Association's Annual Conference. The data showed that APX3330 reduced the worsening of diabetic retinopathy after 24 weeks of treatment. This could potentially shift the treatment paradigm for diabetic retinopathy and broaden the prescriber base to include primary care and endoc..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 28.
  • textsms

Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress

Experts suggest that expanding eligibility for amyotrophic lateral sclerosis (ALS) trials could benefit patients and drug development. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which is an understatement according to investigators. Expanding inclusion criteria would allow more patients to access experimental treatments and help drug develope..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 26.
  • textsms

Expanding ALS Trial Eligibility Could Benefit Patients, Therapeutic Progress

Expanding eligibility criteria for early-phase ALS clinical trials could benefit both patients and therapeutic progress, according to experts. Currently, 60% of ALS patients are excluded from clinical trials by the time they are diagnosed, which has ethical and drug development implications. Angela Genge, chief medical officer at QurAlis, believes that expanding eligibility is necessary to allow..

  • format_list_bulleted Pharmacology/BS
  • · 2023. 6. 23.
  • textsms